Ectatinib belongs to the first generation of targeted drugs, which is a targeted drug developed independently in China. This drug has a relatively high selectivity for epidermal growth factor receptor, also known as EGFR, i.e., it has a certain inhibitory effect on tyrosine kinase. Ectatinib is mainly used clinically in patients with non-small cell lung cancer. Studies have shown that ectatinib is suitable for the treatment of advanced or metastatic non-small cell lung cancer. Ectatinib is often pushed as a first-line agent, and it is also appropriate for patients who have experienced chemotherapy, i.e., patients who have had prior use of platinum-based chemotherapy drugs. During the use of erlotinib, certain side effects may occur, which may cause patients to develop interstitial lung disease and other adverse reactions. During the course of use, care should be taken to monitor for indicators of relevant side effects.